Molecular marker for early screening of breast cancer and application thereof

A molecular marker and breast cancer technology, applied in the field of medicine and biology, can solve the problems of lack of specific early molecular diagnosis methods and great harm, and achieve significant economic and social benefits, low misdiagnosis rate, and high sensitivity

Active Publication Date: 2020-10-13
南京凯弗生物技术有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are many types of breast cancer, which are extremely harmful, but there is still a lack of specific early molecular diagnosis methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker for early screening of breast cancer and application thereof
  • Molecular marker for early screening of breast cancer and application thereof
  • Molecular marker for early screening of breast cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1. Preparation and production of antibodies against phosphorylated 53BP1 protein

[0029] 1. Prepare antibodies against phosphorylated 53BP1 protein by immunizing animals:

[0030] First, design the polypeptides required to prepare antibodies based on the phosphorylation site of 53BP1; design and prepare the phosphorylation site (the 25th and 29th serines) of the protein kinase ATM (ataxia-telangiectasia mutated gene) phosphorylation site in the phosphorylated 53BP1 protein molecule The 53BP1 antigen polypeptide CIED(pS)QPE(pS)QVLEDD, wherein (pS) is serine with phosphate, was synthesized by Hangzhou Dangang Biological Company.

[0031] The phosphorylated 53BP1 antigen polypeptide was coupled to the carrier protein KLH (hemocyanin). Then the antigen solution and the antibody adjuvant (Freund's complete adjuvant or Freund's incomplete adjuvant, Sigma company product) were mixed at a volume ratio of 1:1, and subcutaneously injected into the back of New Zealand wh...

Embodiment 2

[0036] Embodiment 2, the assembly of molecular diagnostic kit and sample test

[0037] 1. Kit assembly

[0038] A specific immunohistochemical staining kit was assembled based on the specific antibody prepared in Example 1. In addition to the above-mentioned specific antibodies, the kit also has the following components:

[0039] Reagent A. Ready-to-use blocking solution, 1 bottle (3ml) of 10% non-immune goat serum

[0040] Reagent B. 1 bottle (3ml) of ready-to-use biotin-labeled goat anti-rabbit secondary antibody (Beyond Biotech, Cat. No. A0277)

[0041] Reagent C. 1 bottle of ready-to-use streptavidin peroxidase (3ml)

[0042] Reagent D. Concentrated Substrate Buffer (20X) 1 bottle (160ul)

[0043] Reagent E.DAB chromogen (20X) 1 bottle (160ul)

[0044] Reagent F. 0.6% H 2 o 2 (20X) 1 bottle (160ul)

[0045] 2. Clinical trials of kits

[0046] Purchase breast cancer tissue chips from Shanghai Zhuohao Pharmaceutical Technology Co., Ltd. (article number BRC2281, see at...

Embodiment 3

[0067] Embodiment 3, sample immunohistochemical staining result analysis

[0068] Image scope X64 software was used to collect immunohistochemical photos, Image pro plus software was used to analyze the results of immunohistochemical staining, and the IOD value of each picture was calculated. The data were statistically analyzed using SPSS 17.0 software, and the difference was considered statistically significant when P<0.01 was tested by an independent sample T test.

[0069] Through immunohistochemical staining technology, the above-mentioned specific phosphorylated 53BP1 antiserum was used to perform immunohistochemical staining on breast cancer tissue chips. A total of 228 cases were stained. The staining results are as follows: figure 1 As shown, the darker the color, the higher the concentration of the target antigen in the sample. Among them, A1, A2, A3, A4, A5, A6, A7, and A8 were 8 non-breast cancer tissue cases, and there were 220 breast cancer tissue cases. In the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a molecular marker for early screening of a breast cancer. The molecular marker is a phosphorylated antigen fragment, a sequence of the molecular marker is shown as SEQ ID NO.1, and serine residues in the antigen are phosphorylated residues. The breast cancer comprises Luminal A, Luminal B, a HER2 positive breast cancer and a triple negative breast cancer. The invention also relates to a detection reagent capable of identifying the molecular marker and a detection kit containing the detection reagent.

Description

technical field [0001] The invention belongs to the field of medical biotechnology, and in particular relates to a molecular marker for early screening of breast cancer and its application. Background technique [0002] Genome instability is an important hallmark of tumor cells. Genome instability is caused by mutation or misexpression of related proteins in cell cycle regulation, DNA replication, and DNA damage repair molecular pathways, resulting in abnormal functions. P53-binding protein 1 (53BP1) is a protein that binds to P53 and was screened by Iwabuchi et al. in 1994 through the yeast two-hybrid system. The molecular weight is 217kDa. 53BP1, as a protein molecule that plays an important role in the repair of DNA double-strand damage (DSB) pathway, can be phosphorylated by protein kinase ATM immediately after DSB occurs and gather at the DNA damage site, which is a recognized marker of DNA double-strand damage one of the molecules. ATM phosphorylates 53BP1 and accum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574C07K16/30C07K16/06
CPCC07K16/065C07K16/3015G01N33/57415G01N33/57484
Inventor 朱长军袁增强张杰廖亚金
Owner 南京凯弗生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap